Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 7th Paris NASH Meeting Sept. 9-10 2021, Paris, France.

Physiogenex to present its 3-week NASH mouse model at the 7th Paris NASH meeting

Dr. François Briand, Director of Research and Business Development, will be presenting a poster entitled “CLINICAL BENCHMARKS AND COMBINATION THERAPY IMPROVE NONALCOHOLIC STEATOHEPATITIS IN A 3-WEEK MOUSE MODEL”. The poster session will be held on September the 9th, 8pm-8:30pm.

If you wish to set an appointment with Dr. François Briand to discuss about your preclinical project, please contact us.

About the 7th Paris NASH meeting

please visit meeting website

About Physiogenex

Physiogenex is a leading preclinical research organization providing non-clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.